BTIG raised the firm’s price target on LifeMD (LFMD) to $15 from $12 and keeps a Buy rating on the shares as part of a broader research note in summary of presentations at the recent Boston Digital Health Summit. The firm believe that nearly all companies in its coverage group can and will benefit from AI, though the direct-to-consumer solutions like LifeMD and Hims (HIMS) may be able to drive more value quickly given the relatively high number of engagements with members, especially with respect to obesity health, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LFMD:
- LifeMD collaborates with Novo Nordisk to launch $299 bundle for Wegovy
- LifeMD’s Earnings Call: Positive Growth and Strategic Expansion
- LifeMD’s Strong Financial Performance and Strategic Initiatives Justify Buy Rating
- LifeMD, Inc. Reports Strong Q1 2025 Results
- LifeMD reports Q1 EPS 1c, consensus 14c